Adecoagro SA vs Ascendis Pharma A/S — how do they compare? Adecoagro SA trades at $9.15 (market cap $1.36B), while Ascendis Pharma A/S trades at $254.63 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 12.3× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| AGRO | ASND | |
|---|---|---|
Market Cap | $1.36B | $16.67B |
Sector | Technology | Health |
52-Week High | $15.25 | $277.18 |
52-Week Low | $7.13 | $189.74 |
Enterprise Value | $3.39B | $17.04B |
Dividend Yield | 3.15% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Trailing returns across standard periods
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →